1 / 12

SALDA Presentation to the Honourable Portfolio Committee on Health

This presentation by SALDA discusses the South African Laboratory Diagnostics Association's support for an independent quality framework in the healthcare sector and the role of in vitro diagnostics in healthcare provision. It also addresses the definition of IVD in the Medicines Act, quality management and quality assurance within the IVD sector, and mandates in other legislation. The presentation also highlights what other countries are doing in terms of quality bodies and raises other important issues related to the National Health Act Amendment Bill.

rosak
Download Presentation

SALDA Presentation to the Honourable Portfolio Committee on Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SALDA Presentation to the Honourable Portfolio Committee on Health National Health Act Amendment Bill B25 -2011 13 March 2012

  2. Who is SALDA • The South African Laboratory Diagnostics Association • Represents >90 % of the In Vitro Diagnostic or laboratory diagnostic industry • Associate member of SAMED as IVD are defined as a medical device • Promotes the field of IVD in the health sector and broader business community SALDA supports a quality framework that is truly independent and that does not duplicate recognised, existing quality systems

  3. How does IVD add value to healthcare provision? Laboratory tests sample HCP orders test Patient Pathologist analyses results HCP receive report & makes therapeutic recommendation

  4. How does IVD add value to healthcare provision? HCP provides self-test / done by HCPs Patient HCP makes therapeutic recommendation

  5. Definition of IVD in the Medicines Act In vitro diagnostic medical device means a medical device, whether used alone or in combination, intended by the manufacturer for the in-vitro examination of specimens derived from the human body solely or principally to provide information for diagnostic, monitoring or compatibility purposes. (as per Act 72 of 2008 (Amendment Act to Medicines and Related Substances Act No 101 of 1965))

  6. Clause 79(1)(f) “quality assurance and quality management systems in the health sector” • The manner in which this is phrased is likely to lead to duplication, and possibly conflicting standards and assessments being made • It applies to the “health sector” and not only “health establishments” (hospitals, practices), this means that the mandate of the South African Health products Regulatory Authority (Act 72) is brought within the ambit of the OHSC • SALDA recognises that this is not the intent, propose re-word (see submission)

  7. What does Quality Management (QM) and Quality Assurance (QA) mean within IVD sector? • QA is a PART of QM • “QA is a set of activities intended to establish confidence that quality requirements will be met” • “QM includes all the activities that organisations use to direct, control and coordinate quality. These activities include formulating a quality policy, setting quality objectives, quality planning, quality control, quality assurance and quality improvement” Source: ISO 9000 “Definitions” 2012

  8. QM and QA already part ofthe IVD Value Chain Manufacturer Laboratory Doctor Patient R&D Manufacturing Marketing Sales Service Training Repairs Process blood samples -> Report on Result E.g. HIV,Chol Interpret Blood/ sample result -> Clinical Decision Treatment Treatment Life style Monitoring

  9. QM and QA mandates by other legislation Manufacturer Laboratory Doctor Patient OHSC: clearly delineated role on quality here Standards Act (SANAS: ISO 15189 – Medical Laboratories Requirements for Quality and Competence); duties of users ito Act 72; NHLS Act Hazardous Substances Act (CE-mark required, i.e. ISO 13485) Act 72 of 2008 (IVD licensing & registration on quality, safety, performance) R&D Manufacturing Marketing Sales Service Training Repairs Process blood samples -> Report on Result E.g. HIV,Chol Interpret Blood result -> Clinical Decision Treatment Treatment Life style Monitoring Health Professions Act (scope of practice & ethical rules) CPA (consumers); Patient Rights Charter

  10. What are other countries doing? • Internationally, quality bodies are totally independent from government organs • Although the intention is to create an independent body, the legislative provisions do not support such independence • Standards are published for comment (prevents overlaps) and developed by experts • Standards must be implemented and becomes an audit – no process and timelines as set internationally. SALDA recommends regulations to be mandated by clause 82A on this aspect) (See SALDA submission on country examples)

  11. Other issues • Objectives of the OHSC (clause 78) only includes “monitoring” but OHSC would accredit and enforce! • Construct of OHSC similar to current MCC (i.e. juristic person and subject to PFMA), but does NOT guarantee that fees could be retained • OHSC must be a Schedule 3 PFMA entity, which normally requires a Board or similar oversight structure (e.g. CMS, SETA’s etc)

  12. Thank you for your time!You are welcome to contact SALDA for more information:Chairperson: Mr Greg Northfield. greg@sepsci.co.za (011) 794-4117Vice chairperson: Dr Terence Moodley terence.moodley@roche.com (011) 504-4600Executive Officer:exec@salda.org.za 0829018715

More Related